Cardiovascular diseases
Achievements
Integrating resources and leading the industry
  • The first product introduced to China
    The first product introduced to China
    1995
  • Core products
    Core products
    1
  • Chinese patients benefited from nearly
    Chinese patients benefited from nearly
    2.0
    million
  • Number of participants
    Number of participants
    45,000
*Data from 2021
Cardiovascular diseases
Development history

Almarl®was launched in 1995 in China and became one of the top three original brands of β-receptor blockers in 2008. We have consistently taken "providing new theories, new knowledge, and new concepts for the prevention and treatment of hypertension" as our primary task; we bring hopes of health to our patients under the great banner of Health China 2030.

2021
Multidisciplinary Expert Consensus on Cardiac Rhythm Management in Chinese Hypertensive Patients
2021
Expert Consensus on the Comprehensive Management of Blood Pressure and Blood Lipids in Chinese Patients with Hypertension
2020
Practice Guidelines for the Comprehensive Management of Primary Cardiovascular Disease
2019
Expert Consensus on the Application of β-receptor Blockers in Hypertension
2019
Guidelines for the Management of Hypertension in the Elderly in China
2019
Hypertension in adults: diagnosis and management by NICE
2019
Expert Guidance on the Application of β-receptor Blockers in Hypertension
2019
Chinese Expert Consensus on the Management of Hypertension in Young and Middle-aged Adults
2019
Guidelines for the Primary Care of Hypertension
2018
Guidelines for the Prevention and Treatment of Hypertension in China (Revised Edition)
2018
Guidelines for the Rational Drug Use for Coronary Heart Disease
2017
Guidelines for the Rational Drug Use for Hypertension (Second Edition)
2017
Expert Consensus on the Cardiac Rhythm Management in Hypertensive Patients (China)
2016
Chinese Expert Consensus on the Application of α-receptor Blockers and β-Receptor Blockers in the Treatment of Hypertension
2013
Practice Guidelines for the use of α-receptor Blockers and β-Receptor Blockers in the Treatment of Hypertension in Chronic Kidney Disease
2009
Guidelines for the Diagnosis and Treatment of Essential Tremor
Cardiovascular diseases
Integrating resources and leading the industry
Copyright @2016 住友制药. All rights reserved  (沪)  -非经营性-2016-0021  沪ICP备16016494号-3   沪公网安备 31010102002939号
You are leaving the official website of
Sumitomo Pharma (Suzhou) Co., Ltd.

You are about to leave the official website of Sumitomo Pharma (Suzhou) Co., Ltd. and be redirected to a third-party website. Please be aware of the risks involved.